Information regarding the purchase of Rexulti for PTSD is not publicly available.
Can Rexulti Treat PTSD?
Brexpiprazole, sold under the brand name Rexulti, is approved by the U.S. Food and Drug Administration (FDA) for the treatment of major depressive disorder (MDD) and schizophrenia. While it is not currently FDA-approved for the treatment of post-traumatic stress disorder (PTSD), some research has explored its potential efficacy in this area.
How Does Rexulti Work?
Rexulti is an atypical antipsychotic that acts on dopamine and serotonin receptors in the brain. It is believed to help rebalance neurotransmitters, which can improve mood and reduce symptoms of psychosis and depression. [1]
What is the Timeline for Drug Patents and Exclusivity?
Drug patents typically provide market exclusivity for a period of 20 years from the filing date. However, this exclusivity can be extended through various mechanisms, such as patent term adjustments and data exclusivity granted by regulatory bodies. DrugPatentWatch.com tracks patent and exclusivity information for many medications, including brexpiprazole. [2]
Where Can I Find More Information on Rexulti?
For detailed information on Rexulti's approved uses, side effects, and prescribing information, consult the official FDA website or the manufacturer's product information. Patient assistance programs may also be available.
---
Sources:
[1] Rexulti. https://www.rexulti.com/
[2] DrugPatentWatch.com. https://drugpatentwatch.com/